Remdesivir with Brilacidin which resulted in a 99.85% Viral Load Reduction

Who's seen this, Amazing Brilacidin/Remdesivir Combination: In a test at the George Mason University RBL, the Lab combined Remdesivir with Brilacidin which resulted in a 99.85% Viral Load Reduction with insignificant traces of the virus remaining.

http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent

 

Why wouldn't we buy out Innovation Pharmaceutical's before they become the gold standard for COVID and others, Brilacidin's clinical data looks amazing!

COVID-19 Drug Candidate Brilacidin Achieves a Selectivity Index Among the Highest Reported, Exhibiting Potent Anti-SARS-CoV-2 Activity at Low Concentrations; Clinical Trial Forthcoming — Innovation Pharmaceuticals Inc.

 

In the RBL assay (which included Brilacidin pre-incubated with virus), Brilacidin exhibited approximately 90 percent inhibition against SARS-CoV-2 at a concentration similar to that of Remdesivir™, which again reported 50 percent inhibition of the coronavirus. The Brilacidin inhibition assay was tested in a human lung epithelial cell line, with Remdesivir™ tested in Vero cells. The RBL data also supports Brilacidin showing an ability to inhibit viral entry into cells, a highly desirable mechanism of action as it is the first step in the infection process enabling viruses to be targeted outside the cell, whereas Remdesivir™ impacts viral replication only after the host cell has been infected.

Innovation Pharmaceuticals’ Brilacidin Inhibits Novel Coronavirus (COVID-19) by Almost 90% at the Lowest Concentration Tested to Date in a Human Lung Cell Line — Innovation Pharmaceuticals Inc.

 

Vitro is coming, I'm strongly expecting the stock price to explode soon. Innovation Pharmaceuticals has already announced in early October that a Pre-IND Meeting Request was granted by the FDA for the Study of Brilacidin for the Treatment of COVID-19

"In the application, the Company has requested regulatory guidance on its planned Phase 2, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of Brilacidin in hospitalized patients with COVID-19. Target enrollment is 120 patients, with a planned interim analysis"

"Extensive pre-clinical research, nearing completion, conducted at independent laboratories reinforces the antiviral potential of Brilacidin against SARS-CoV-2, the novel coronavirus responsible for COVID-19. Numerous hospitals and provider networks domestically and abroad have expressed a strong interest in participating in the Brilacidin for COVID-19 clinical trial. Given such interest in Brilacidin, the Company anticipates the planned COVID-19 trial can be rapidly recruited and completed."

 

Do we really need a sales force when there is already a shortage of the drug. Public opinion will not be good with the world wide pandemic.

 

Might turn into standard protocol across all hospitals. 99% is almost eradicating viral load. Cant get better than that.
I m sure combo side effects will need to be studied before even an EU indication thus min of a year away. Likely late 2022
Enough time for an acquisition.

 

Gold Standard baby

 

VKY paid all the Hep & Onc & HQ & Dan & Joanna bonuses while VKY reps got the dry shaft